Hims & Hers Health (NYSE:HIMS - Get Free Report) had its target price lifted by research analysts at TD Cowen from $25.00 to $28.00 in a report issued on Friday,Benzinga reports. The firm presently has a "buy" rating on the stock. TD Cowen's price objective suggests a potential upside of 19.58% from the stock's previous close.
A number of other research analysts also recently commented on HIMS. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a "hold" rating in a research note on Wednesday. Imperial Capital cut shares of Hims & Hers Health from an "outperform" rating to an "in-line" rating in a research report on Friday, August 9th. Truist Financial boosted their price objective on Hims & Hers Health from $13.00 to $23.00 and gave the company a "hold" rating in a report on Thursday, July 18th. Piper Sandler reaffirmed a "neutral" rating and set a $21.00 target price (up previously from $18.00) on shares of Hims & Hers Health in a report on Tuesday. Finally, Needham & Company LLC started coverage on Hims & Hers Health in a research report on Thursday, August 22nd. They issued a "buy" rating and a $24.00 target price for the company. Eight research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $21.21.
Check Out Our Latest Stock Report on HIMS
Hims & Hers Health Stock Down 0.9 %
Shares of Hims & Hers Health stock traded down $0.21 during trading hours on Friday, hitting $23.42. 17,964,709 shares of the company's stock traded hands, compared to its average volume of 13,702,758. Hims & Hers Health has a twelve month low of $6.58 and a twelve month high of $25.74. The company has a market cap of $5.03 billion, a PE ratio of 53.22 and a beta of 1.06. The stock has a 50 day simple moving average of $18.57 and a 200-day simple moving average of $18.33.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating analysts' consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. During the same quarter last year, the firm earned ($0.04) EPS. Hims & Hers Health's quarterly revenue was up 77.1% on a year-over-year basis. As a group, equities research analysts predict that Hims & Hers Health will post 0.22 EPS for the current year.
Insider Buying and Selling
In other Hims & Hers Health news, CFO Oluyemi Okupe sold 269,739 shares of the business's stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $20.31, for a total transaction of $5,478,399.09. Following the completion of the transaction, the chief financial officer now directly owns 145,763 shares of the company's stock, valued at $2,960,446.53. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, CEO Andrew Dudum sold 188,888 shares of the firm's stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the transaction, the chief executive officer now directly owns 33,502 shares of the company's stock, valued at approximately $487,789.12. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Oluyemi Okupe sold 269,739 shares of Hims & Hers Health stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $20.31, for a total transaction of $5,478,399.09. Following the sale, the chief financial officer now owns 145,763 shares in the company, valued at approximately $2,960,446.53. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 854,547 shares of company stock valued at $15,987,230 in the last quarter. Company insiders own 17.71% of the company's stock.
Hedge Funds Weigh In On Hims & Hers Health
Several large investors have recently bought and sold shares of the stock. Nisa Investment Advisors LLC boosted its holdings in shares of Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company's stock valued at $37,000 after acquiring an additional 1,603 shares in the last quarter. Quest Partners LLC lifted its position in Hims & Hers Health by 5,944.1% in the second quarter. Quest Partners LLC now owns 3,566 shares of the company's stock worth $72,000 after purchasing an additional 3,507 shares during the period. CWM LLC boosted its stake in Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company's stock valued at $110,000 after purchasing an additional 1,054 shares in the last quarter. Van ECK Associates Corp acquired a new position in shares of Hims & Hers Health during the 2nd quarter valued at $111,000. Finally, Amalgamated Bank raised its stake in shares of Hims & Hers Health by 55.9% in the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company's stock worth $133,000 after buying an additional 2,354 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.
About Hims & Hers Health
(
Get Free Report)
Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.
See Also
Before you consider Hims & Hers Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims & Hers Health wasn't on the list.
While Hims & Hers Health currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.